Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

NCT00290394 | Completed Phase 4

• 1 other identifier: KA03/181
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.

Conditions

Diabetes Mellitus, Type 2

Keywords

Blood Pressure,; rosiglitazone,Diabetes Mellitus, Type 2,

Outcome Measures

Primary Outcomes (1)

• Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.

Interventions

rosiglitazone(drug), blood pressure lowering effect DRUG

Eligibility Criteria

• Age: 49 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Blood pressure of patients were in normotensive limits according to the JNC VII
• Diabetes mellitus treated with oral antidiabetics or diet

You may not qualify if:

• Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease
• Anti-hypertensive treatment

Sponsors & Collaborators

• Baskent University: lead

Study Sites (1)

Baskent University Ankara Hospital

Ankara, 06490, Turkey (Türkiye)

Location

Related Publications (6)

• Takano H, Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications. 2002 Jan-Feb;16(1):108-14. doi: 10.1016/s1056-8727(01)00203-3.

  PMID: 11872377 BACKGROUND

• Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes. 1998 May;47(5):810-4. doi: 10.2337/diabetes.47.5.810.

  PMID: 9588454 BACKGROUND

• Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens. 1998 Sep;11(9):1134-7. doi: 10.1016/s0895-7061(98)00130-7.

  PMID: 9752901 BACKGROUND

• Chen S, Noguchi Y, Izumida T, Tatebe J, Katayama S. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens. 1996 Nov;14(11):1325-30. doi: 10.1097/00004872-199611000-00011.

  PMID: 8934361 BACKGROUND

• Saku K, Zhang B, Ohta T, Arakawa K. Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am J Hypertens. 1997 Sep;10(9 Pt 1):1027-33. doi: 10.1016/s0895-7061(97)00160-x.

  PMID: 9324109 BACKGROUND

• Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994 Nov 3;331(18):1188-93. doi: 10.1056/NEJM199411033311803.

  PMID: 7935656 BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Neslihan B Tutuncu, MD

  Medical Doctor, Endocrynology

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 9, 2006
• First Posted: February 13, 2006
• Study Start: March 1, 2004
• Study Completion: August 1, 2004
• Last Updated: February 13, 2006

Record last verified: 2004-03

Locations

TU (1)